Bal Pharma announced that the Board of Directors of the Company at its meeting held on 28 May 2024, inter alia, have recommended the final dividend of Rs 1.2 per equity Share (i.e. 12%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Bal Pharma rose 241.88% to Rs 5.47 crore in the quarter ended March 2024 as against Rs 1.60 crore during the previous quarter ended March 2023. Sales rose 14.77% to Rs 94.63 crore in the quarter ended March 2024 as against Rs 82.45 crore during the previous quarter ended March 2023.For the full year,net profit rose 187.55% to Rs 7.39 crore in the year ended March 2024 as against Rs 2.57 crore during the previous year ended March 2023. Sales rose 11.50% to Rs 339.22 crore in the year ended March 2024 as against Rs 304.22 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales94.6382.45 15 339.22304.22 12 OPM %10.149.90 -9.298.35 - PBDT7.914.50 76 19.1213.88 38 PBT5.752.41 139 9.054.75 91 NP5.471.60 242 7.392.57 188 Powered by Capital Market - Live News

Bal Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2024.Powered by Capital Market - Live News

Net profit of Bal Pharma rose 56.14% to Rs 0.89 crore in the quarter ended December 2023 as against Rs 0.57 crore during the previous quarter ended December 2022. Sales rose 6.58% to Rs 81.66 crore in the quarter ended December 2023 as against Rs 76.62 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales81.6676.62 7 OPM %9.548.03 - PBDT4.233.50 21 PBT1.271.05 21 NP0.890.57 56 Powered by Capital Market - Live News

Bal Pharma will hold a meeting of the Board of Directors of the Company on 12 February 2024.Powered by Capital Market - Live News